Cargando…
Plasma protein profiling of Mild Cognitive Impairment and Alzheimer’s disease using iTRAQ quantitative proteomics
BACKGROUND: With the promise of disease modifying treatments, there is a need for more specific diagnosis and prognosis of Alzheimer’s disease (AD) and mild cognitive impairment (MCI). Plasma biomarkers are likely to be utilised to increase diagnostic accuracy and specificity of AD and cognitive dec...
Autores principales: | Song, Fei, Poljak, Anne, Kochan, Nicole A, Raftery, Mark, Brodaty, Henry, Smythe, George A, Sachdev, Perminder S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898732/ https://www.ncbi.nlm.nih.gov/pubmed/24433274 http://dx.doi.org/10.1186/1477-5956-12-5 |
Ejemplares similares
-
Upregulation of Glycolytic Enzymes, Mitochondrial Dysfunction and Increased Cytotoxicity in Glial Cells Treated with Alzheimer’s Disease Plasma
por: Jayasena, Tharusha, et al.
Publicado: (2015) -
i-Tracker: For quantitative proteomics using iTRAQ™
por: Shadforth, Ian P, et al.
Publicado: (2005) -
Microstructural White Matter Changes, Not Hippocampal Atrophy, Detect Early Amnestic Mild Cognitive Impairment
por: Zhuang, Lin, et al.
Publicado: (2013) -
Plasma Apolipoprotein Levels Are Associated with Cognitive Status and Decline in a Community Cohort of Older Individuals
por: Song, Fei, et al.
Publicado: (2012) -
The Sub-Classification of Amnestic Mild Cognitive Impairment Using MRI-Based Cortical Thickness Measures
por: Raamana, Pradeep Reddy, et al.
Publicado: (2014)